Stockreport

Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa [Yahoo! Finance]

Novartis AG  (NVS) 
Last novartis ag earnings: 4/28 01:00 am Check Earnings Report
US:NYSE Investor Relations: novartis.com/investors
PDF Novartis Pharma AG Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade HS often emerges ar [Read more]